Douglas Sanders, Ph.D., VP Head of Translational Medicine at AVROBIO provides detailed examples of the diseases that are a better fit for AAV or ex vivo lentiviral gene therapy and why.
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Please enter your email address and create a password to access the full content, Or
log in to your account to continue.
Please tell us more about you so that we can customize our newsletters to your specific interests: